Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.
about
The identification of specific methylation patterns across different cancersErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma.Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy
P2860
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dual targeting of ErbB-2/ErbB- ...... l models of pancreatic cancer.
@en
Dual targeting of ErbB-2/ErbB- ...... l models of pancreatic cancer.
@nl
type
label
Dual targeting of ErbB-2/ErbB- ...... l models of pancreatic cancer.
@en
Dual targeting of ErbB-2/ErbB- ...... l models of pancreatic cancer.
@nl
prefLabel
Dual targeting of ErbB-2/ErbB- ...... l models of pancreatic cancer.
@en
Dual targeting of ErbB-2/ErbB- ...... l models of pancreatic cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Dual targeting of ErbB-2/ErbB- ...... l models of pancreatic cancer.
@en
P2093
I G Rapposelli
M Piantelli
S Iacobelli
P2860
P2888
P356
10.1038/ONCSIS.2014.31
P577
2014-08-18T00:00:00Z
P5875
P6179
1042182906